Cullinan Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cullinan Therapeutics, Inc. (CGEM) on January 8, 2026. The filing provides a corporate update, preliminary financial data as of December 31, 2025, and anticipated clinical milestones for 2026 across its immunology and oncology pipelines.
Key Financial Metrics
- Cash and Investments: As of December 31, 2025, the Company reported preliminary, unaudited cash, cash equivalents, short- and long-term investments, and interest receivable totaling $439.0 million.
- Liquidity Runway: Management expects current cash resources to provide a runway into 2029 based on the current operating plan.
- Revenue and Profit: The filing does not provide specific revenue, profit, or margin figures for the period.
- Debt: The filing does not disclose specific debt levels.
Material Changes and Program Updates
The filing details significant progress in clinical development and regulatory milestones:
- CLN-978 (Immunology): Dose escalation is ongoing in Phase 1 studies for rheumatoid arthritis, systemic lupus erythematosus, and Sjögren's disease. Initial data from single target dose escalation is expected in Q2 2026 for rheumatoid arthritis and lupus, and Q4 2026 for Sjögren's disease.
- Velinotamig (Immunology): Partner Genrix initiated a Phase 1 study in China in December 2025, with initial data expected in Q4 2026.
- CLN-049 (Oncology): Received FDA Fast Track designation for relapsed/refractory acute myeloid leukemia (AML) in December 2025. Monotherapy dose expansion cohorts are expected to initiate in Q2 2026.
- Zipalertinib (Oncology): Partner Taiho initiated a rolling New Drug Application (NDA) submission in November 2025 for relapsed EGFR ex20ins NSCLC, with completion expected in Q1 2026. Cullinan is eligible for up to $130.0 million in U.S. regulatory milestone payments and 50% of future pre-tax profits from U.S. sales.
Guidance, Outlook, and Risks
Management anticipates sharing initial clinical data for multiple programs throughout 2026, with a focus on safety, biomarker data, and preliminary clinical activity. The Company highlights that the reported cash position is preliminary and unaudited, subject to change upon completion of financial closing procedures. Forward-looking statements are subject to risks including market conditions, clinical trial outcomes, and regulatory approvals.
Investor Verification Checklist
- Verify the final audited cash position upon the release of the 2025 Annual Report (10-K).
- Monitor the status of Taiho's rolling NDA submission for zipalertinib and the timeline for FDA review.
- Track the release of initial data from the CLN-978 and CLN-049 studies in Q2 and Q4 2026 as scheduled.
- Confirm the initiation of the CLN-049 monotherapy dose expansion cohorts in Q2 2026.